Which patient groups primarily use sapropterin?

Who uses sapropterin most often?

Sapropterin treats patients with phenylketonuria (PKU) who show some response to the drug in a loading test. Doctors prescribe it mainly for children and adults with mild or moderate forms of the condition. Patients who maintain phenylalanine levels below 360 µmol/L on the drug often continue long-term treatment.

What happens if a patient shows no response?

Non-responders do not receive ongoing sapropterin therapy. They rely instead on strict phenylalanine-restricted diets alone. Testing a patient’s response takes four weeks of daily administration at 20 mg/kg/day, followed by blood phenylalanine measurements.

How does sapropterin reduce phenylalanine levels?

The drug activates residual phenylalanine hydroxylase enzyme activity. In PKU patients who have some working enzyme, it lowers blood phenylalanine by 20–30% on average. This reduction helps patients relax their dietary limits compared with diet alone.

Can sapropterin be used in pregnancy?

Pregnant women with PKU who respond to sapropterin may use the drug to maintain safer phenylalanine levels. Data from registries show maternal phenylalanine levels under control with no excess birth defects reported in responsive cases. Registries continue to collect data on long-term outcomes.

How does sapropterin compare with enzyme replacement therapy?

Sapropterin requires oral tablets taken once daily. Enzyme replacement therapy requires subcutaneous injections several times a week. Patients who respond to sapropterin prefer it over injection-based alternatives because it is non-invasive.